A meta-analysis of six randomized controlled trials (RCTs) from the “Liraglutide Effect and Action in Diabetes (LEAD)” program found that 26 weeks of treatment with liraglutide (1.8 mg/day) led to improvements in alanine aminotransferase (ALT) levels and hepatic steatosis in 4442 patients with type 2 diabetes (T2DM) [121]. The gene discussed is GPT; the disease is fatty liver disease.